Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador

Vista sencilla de ítem
dc.contributor.authorGomez Contreras, María Camila
dc.contributor.authorSguerra Bergsneider, María Paula
dc.contributor.authorEstupiñan Dueñas, Lizeth Idaly
dc.contributor.authorBernal Alarcón, Diego Nicolás
dc.contributor.authorCastañeda Saavedra, Stefania de los Ángeles
dc.contributor.authorAlbarracin Ruiz, Maria Jose
dc.contributor.authorCano Rosales, Diana Jimena
dc.contributor.cvlacGomez Contreras, María Camila [0001664780]spa
dc.contributor.cvlacAlbarracín Ruiz, María José [0001649451]spa
dc.contributor.cvlacCano Rosales, Diana Jimena [0000947237]spa
dc.contributor.orcidGomez Contreras, María Camila [0000-0003-0542-4622]spa
dc.contributor.orcidBernal Alarcón, Diego Nicolás [0000-0003-2072-9731]spa
dc.contributor.orcidCano Rosales, Diana Jimena [0000-0002-7090-5142]spa
dc.contributor.researchgroupSemilleros de Investigación UNABspa
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.coverage.temporal2018spa
dc.date.accessioned2023-09-05T19:32:43Z
dc.date.available2023-09-05T19:32:43Z
dc.date.issued2018-11
dc.description.abstractLa enfermedad pulmonar obstructiva crónica (EPOC) es una enfermedad común, prevenible y tratable, con alta carga de morbimortalidad y gran uso de recursos en salud, que se caracteriza por síntomas respiratorios persistentes y limitaciónen el tracto respiratorio secundario. Se reportó como la cuarta causa de muerte en el mundo en el año 2010 y en Colombia como la quinta causa de mortalidad prematura, contribuyendo en gran parte a años de vida perdidos por enfermedad. En pacientes con EPOC, la respuesta inflamatoria generada por mediadores proinflamatorios que infiltran el epitelio aéreo promueven estrés oxidativo que ocasiona el compromiso de la vía aérea cuyas manifestaciones clínicas son el broncoespasmo, edema y persistencia de la inflamación local. El estrés oxidativo generado es un factor determinante en la progresión de la enfermedad, interviene crónicamente en la inflamación bronquial y parenquimatosa pulmonar; se han descrito intervenciones con el fin de disminuirlo como el suplemento de antioxidantes sintéticos o dietéticos y la modificación de factores ambientales que promueven la oxidación como el Zinc. Existe controversia sobre la influencia de los niveles de zinc en pacientes con enfermedades respiratorias. La investigación se ha centrado en pacientes asmáticos y se ha estudiado en menor proporción en los pacientes con EPOC, en los cuales la evidencia sobre el zinc es mínima y no hay un consenso que separe el manejo dietario con suplementos como el zinc en los pacientes con fenotipo exacerbador frecuente versus el fenotipo no exacerbador. A través de este estudio, se propone medir marcadores inflamatorios, se propone medir marcadores inflamatorios de estrés oxidativo y de sustancias relacionadas con la inflamación en los pacientes con EPOC, para determinar el impacto de estos niveles séricos en las exacerbaciones en nuestra población a estudio.spa
dc.description.abstractenglishChronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable disease. COPD has a high rate of morbidity and mortality and it also, implies a high use of health resources. COPD is characterised by persistent respiratory symptoms and limitation of the secondary respiratory tract. It was eported as the fourth highest cause of prematue mortality in the world, and fifth locally, in Colombia. Which is reflected in contribution to the huge amount of loss life years because of a disease. In Patients with COPD, the inflammatory response is generated by pro inflammatory mediators which cross the airway epithelium promoting oxidative stress, which further compromises the airway; Its clinic hallmarks are bronchospasm, edema, and persistent local inflammation. Generated oxidative stressis a core factor in the disease evolution, it chronically intervenes in the bronchial and pulmonary parenchymal inflammation. It has been described interventions with the purpose of diminish it as a supplement of synthetic or dietetic antioxidants and the modification of environmental factors which promote the oxidation, such as Zinc. A controversy exists about the Zinc levels influence on patients with respiratory diseases. The research has focused on asthmatic patients, leaving COPD patients in fewer proportion, where is possessed minimal evidence about Zinc influence. There is also no consensus which differentiates the dietary management of supplements such as Zinc, in patients with exacerbator phenotype against with non-exacerbator phenotype Calculating markers of inflammation is proposed through this study, specifically those related with oxidative stress and pro inflammation substances in COPD patients. In order to determine the relative impact of these serum levels in the exacerbations of our designated study population.spa
dc.description.learningmodalityModalidad Presencialspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.issnISSN 2344-7079spa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/21674
dc.language.isospaspa
dc.publisher.deparmentSistema de Investigación SIUNABspa
dc.publisher.facultyFacultad Ciencias de la Salud
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.publisher.programPregrado Medicina
dc.relation.ispartofseriesGeneración Creativa : Encuentro de Semilleros de Investigación UNABspa
dc.relation.references1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar;195(5):557–82.spa
dc.relation.references2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012 Dec;380(9859):2095–128.spa
dc.relation.references3. WHO | The global burden. WHO [Internet]. 2010 [cited 2017 Sep 21]; Available from: http://who.int/substance_abuse/facts/global_burden/en/spa
dc.relation.references4. Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J [Internet]. 2010 Jul 1 [cited 2017 Sep 21];36(1):96–104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19897551spa
dc.relation.references5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J [Internet]. 2009 May 1 [cited 2017 Sep 21];33(5):1165–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19407051spa
dc.relation.references6. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet [Internet]. 2007 Sep 1 [cited 2017 Sep 21];370(9589):797–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17765529spa
dc.relation.references7. Rerksuppaphol S, Rerksuppaphol L. Zinc Supplementation in Children with Asthma Exacerbation. Pediatr Rep [Internet]. 2016 Nov 17 [cited 2017 Sep 21];8(4):6685. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28058103spa
dc.relation.references8. Riccioni G, D’Orazio N. The role of selenium, zinc and antioxidant vitamin supplementation in the treatment of bronchial asthma: adjuvant therapy or not? Expert Opin Investig Drugs [Internet]. 2005 Sep 22 [cited 2017 Sep 21];14(9):1145–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16144498spa
dc.relation.references9. Guo C-H, Liu P-J, Lin K-P, Chen P-C. Nutritional supplement therapy improves oxidative stress, immune response, pulmonary function, and quality of life in allergic asthma patients: an open-label pilot study. Altern Med Rev [Internet]. 2012 Mar [cited 2017 Sep 19];17(1):42–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22502622spa
dc.relation.references10. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet [Internet]. 2012 Dec 15 [cited 2017 Sep 14];380(9859):2197–223. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23245608spa
dc.relation.references11. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet [Internet]. 2004 Aug [cited 2017 Sep 14];364(9434):613– 20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15313363spa
dc.relation.references12. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev [Internet]. 2009 [cited 2017 Sep 13];18(114). Available from: http://err.ersjournals.com/content/18/114/213#T2spa
dc.relation.references13. Menezes AMB, Perez-Padilla R, Jardim JRB, Muiño A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet (London, England). 2005 Nov;366(9500):1875–81.spa
dc.relation.references14. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343–9.spa
dc.relation.references15. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2010 Sep 16 [cited 2017 Sep 14];363(12):1128– 38. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0909883spa
dc.relation.references16. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir Res [Internet]. 2009 Dec 30 [cited 2017 Sep 14];10(1):59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19566934spa
dc.relation.references17. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet [Internet]. 2009 Oct 3 [cited 2017 Sep 14];374(9696):1171–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19716598spa
dc.relation.references18. Soler-Cataluna JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax [Internet]. 2005 Nov 1 [cited 2017 Sep 14];60(11):925–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16055622spa
dc.relation.references19. Pauwels RA, Löfdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking. N Engl J Med. 1999 Jun;340(25):1948–53.spa
dc.relation.references20. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (London, England). 1999 May;353(9167):1819–23.spa
dc.relation.references21. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2008 Oct 9 [cited 2017 Sep 12];359(15):1543–54. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0805800spa
dc.relation.references22. O’Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6).spa
dc.relation.references23. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest. 2006 Sep;130(3):647–56.spa
dc.relation.references24. Zalewski PD, Truong-Tran AQ, Grosser D, Jayaram L, Murgia C, Ruffin RE. Zinc metabolism in airway epithelium and airway inflammation: Basic mechanisms and clinical targets. A review. Pharmacol Ther. 2005;105(2):127–49.spa
dc.relation.references25. Zalewski PD. Zinc metabolism in the airway: basic mechanisms and drug targets. Curr Opin Pharmacol. 2006;6(3):237–43.spa
dc.relation.references26. Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci [Internet]. 2003 Feb [cited 2017 Sep 19];28(1):7–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12682418spa
dc.relation.references27. Kondo T, Tagami S, Yoshioka A, Nishimura M, Kawakami Y. Current smoking of elderly men reduces antioxidants in alveolar macrophages. Am J Respir Crit Care Med [Internet]. 1994 Jan [cited 2017 Sep 19];149(1):178–82. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm.149.1.8 111579spa
dc.relation.references28. Di Toro R, Galdo Capotorti G, Gialanella G, Miraglia del Giudice M, Moro R, Perrone L. Zinc and copper status of allergic children. Acta Paediatr Scand [Internet]. 1987 Jul [cited 2017 Sep 19];76(4):612–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3630679spa
dc.relation.references29. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids [Internet]. 2000 Sep [cited 2017 Sep 19];35(9):967– 74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11026617spa
dc.relation.references30. el-Kholy MS, Gas Allah MA, el-Shimi S, el-Baz F, elTayeb H, Abdel-Hamid MS. Zinc and copper status in children with bronchial asthma and atopic dermatitis. J Egypt Public Health Assoc [Internet]. 1990 [cited 2017 Sep 19];65(5–6):657–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2134100spa
dc.relation.references31. Kadrabová J, Mad’aric A, Podivínsky F, Gazdík F, Ginter F. Plasma zinc, copper and copper/zinc ratio in intrinsic asthma. J Trace Elem Med Biol [Internet]. 1996 Apr [cited 2017 Sep 19];10(1):50–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8793823spa
dc.relation.references32. Kirkil G, Hamdi Muz M, Seçkin D, Sahin K, Küçük O. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med [Internet]. 2008;102(6):840–4. Available from: www.pubmed.govspa
dc.relation.urihttp://hdl.handle.net/20.500.12749/14242
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.localAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.sourceGomez, M. C., et al. (2018). Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador. Recuperado de: http://hdl.handle.net/20.500.12749/21674spa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsClinical investigationsspa
dc.subject.keywordsInternal medicinespa
dc.subject.keywordsPneumologyspa
dc.subject.keywordsInvestigationspa
dc.subject.keywordsCOPDspa
dc.subject.keywordsOxidative stressspa
dc.subject.keywordsSerum zinc levelsspa
dc.subject.keywordsExacerbator phenotypespa
dc.subject.lembCiencias de la saludspa
dc.subject.lembInvestigaciones clínicasspa
dc.subject.lembMedicina internaspa
dc.subject.lembNeumologíaspa
dc.subject.lembInvestigaciónspa
dc.subject.proposalEPOCspa
dc.subject.proposalEstrés oxidativospa
dc.subject.proposalNiveles de zinc séricospa
dc.subject.proposalFenotipo exacerbadorspa
dc.titleNiveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbadorspa
dc.title.translatedZinc Levels in Patients With COPD Phenotype exacerbatorspa
dc.typeConferenceeng
dc.type.coarhttp://purl.org/coar/resource_type/c_f744
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.driverinfo:eu-repo/semantics/conferenceProceedingsspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localMemoria de eventosspa
dc.type.redcolhttp://purl.org/redcol/resource_type/EC_AC

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
2018_Articulo_Gomez_Contreras_Maria_Camila.pdf
Tamaño:
268.19 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
829 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Memoria de eventos: Generación Creativa. Encuentro de Semilleros de Investigación UNAB